Condition
Flavivirus Infections
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Unknown1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07543458Phase 3Not Yet Recruiting
Therapeutics for Moderate and Severe Dengue
NCT03110770Phase 2Completed
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
NCT05919277Unknown
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
NCT03343626Phase 1Completed
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants
Showing all 4 trials